Targeted Agent Bests Chemo in Second-Line for KRAS-Mutant NSCLC

(MedPage Today) -- Targeted therapy with sotorasib (Lumakras) in previously treated non-small cell lung cancer (NSCLC) patients harboring KRAS-G12C mutations reduced the risk of disease progression or death by 34% compared with standard second...